J&J Medical Connect
SPRAVATO®

(esketamine)

+ Save link
J&J Medical Connect

Connect with us

Connect with us

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

SPRAVATO® (esketamine)

Medical Information

Use of SPRAVATO in Patients with Postpartum Depression

Last Updated: 10/30/2025

SUMMARY  

  • SPRAVATO is not indicated for the treatment of postpartum depression.
  • Clinical studies designed to evaluate the efficacy and/or safety of SPRAVATO in patients with postpartum depression have not been performed.
  • SPRAVATO is not recommended in women who are breastfeeding.1  
    • The risks of SPRAVATO during breastfeeding have not been studied in humans. There is no data available to assess the effects of SPRAVATO on human milk production or effects on the breastfed infant.

PRODUCT LABELING

  • SPRAVATO is not recommended in women who are breastfeeding.2 
    • SPRAVATO is present in human milk.
    • There is no data available to assess the effects of SPRAVATO on human milk production or effects on the breastfed infant.
    • Because of the potential for neurotoxicity, advise patients that breastfeeding is not recommended during treatment with SPRAVATO.

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, DERWENT® (and/or other resources, including internal/external databases) conducted on 27 October 2025 did not identify any relevant citations pertaining to this topic.

 

References

Show
1 Data on File. Esketamine. Core Company Data Sheet. Janssen Research & Development, LLC. EDMS-ERI-122750672. V13; 2025.  
2 SPRAVATO (esketamine) nasal spray [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf